- Home
- HOMB vs GRFS Comparison
HOMB vs GRFS Comparison
Compare HOMB & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HOMB | GRFS |
|---|---|---|
| Founded | 1998 | 1940 |
| Country | United States | Spain |
| Employees | N/A | 25247 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.4B |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | HOMB | GRFS |
|---|---|---|
| Price | $27.61 | $7.37 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $31.50 | $10.15 |
| AVG Volume (30 Days) | ★ 1.4M | 521.9K |
| Earning Date | 04-15-2026 | 07-28-2022 |
| Dividend Yield | ★ 3.17% | 1.80% |
| EPS Growth | ★ 19.90 | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.99 | $4.49 |
| Revenue Next Year | $5.14 | $6.42 |
| P/E Ratio | $46.00 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.50 | $7.26 |
| 52 Week High | $30.83 | $11.14 |
Technical Indicators
Market Signals| Indicator | HOMB | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 56.43 | 39.71 |
| Support Level | $26.08 | $7.38 |
| Resistance Level | $28.72 | $8.88 |
| Average True Range (ATR) | 0.49 | 0.17 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 62.55 | 20.90 |
Price Performance
Historical ComparisonAbout HOMB Home BancShares Inc.
Home BancShares Inc is a bank holding company that operates through its wholly owned community bank subsidiary, Centennial Bank. The bank provides a broad range of commercial and retail banking, as well as related financial services, to a diverse customer base. Its customer base includes businesses, real estate developers and investors, individuals, and municipalities. The company's loan portfolio, while diversified, is typically between half and two thirds in commercial real estate loans. The company's plan emphasizes growth, both through strategic acquisitions and organically within its existing markets. The company has one reportable segment: The Banking Segment.
About GRFS Grifols S.A.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.